Free Trial

Lexeo Therapeutics (LXEO) Competitors

→ He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad)
Free LXEO Stock Alerts
$13.14
-1.36 (-9.38%)
(As of 05/10/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

LXEO vs. TRML, ITOS, TCRX, REPL, ADPT, SLDB, AURA, CCCC, ALVO, and TNYA

Should you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Tourmaline Bio (TRML), iTeos Therapeutics (ITOS), TScan Therapeutics (TCRX), Replimune Group (REPL), Adaptive Biotechnologies (ADPT), Solid Biosciences (SLDB), Aura Biosciences (AURA), C4 Therapeutics (CCCC), Alvotech (ALVO), and Tenaya Therapeutics (TNYA). These companies are all part of the "biological products, except diagnostic" industry.

Lexeo Therapeutics vs.

Tourmaline Bio (NASDAQ:TRML) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Tourmaline Bio's return on equity of 0.00% beat Lexeo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tourmaline BioN/A -30.86% -29.30%
Lexeo Therapeutics N/A N/A -71.37%

Tourmaline Bio received 3 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
Tourmaline BioOutperform Votes
9
100.00%
Underperform Votes
No Votes
Lexeo TherapeuticsOutperform Votes
6
100.00%
Underperform Votes
No Votes

91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 11.0% of Tourmaline Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tourmaline Bio presently has a consensus target price of $61.80, suggesting a potential upside of 326.21%. Lexeo Therapeutics has a consensus target price of $20.80, suggesting a potential upside of 58.30%. Given Lexeo Therapeutics' higher possible upside, equities analysts plainly believe Tourmaline Bio is more favorable than Lexeo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tourmaline Bio
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Lexeo Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Tourmaline Bio has higher earnings, but lower revenue than Lexeo Therapeutics. Tourmaline Bio is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tourmaline BioN/AN/A-$42.12M-$11.35-1.28
Lexeo Therapeutics$650K665.89-$66.39M-$22.29-0.59

In the previous week, Lexeo Therapeutics had 2 more articles in the media than Tourmaline Bio. MarketBeat recorded 6 mentions for Lexeo Therapeutics and 4 mentions for Tourmaline Bio. Lexeo Therapeutics' average media sentiment score of 0.87 beat Tourmaline Bio's score of 0.08 indicating that Tourmaline Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tourmaline Bio
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lexeo Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Tourmaline Bio beats Lexeo Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Lexeo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LXEO vs. The Competition

Export to Excel
MetricLexeo TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$432.83M$2.83B$5.09B$7.80B
Dividend YieldN/A2.25%37.43%3.91%
P/E Ratio-0.5914.55141.6516.61
Price / Sales665.89312.622,421.8976.09
Price / CashN/A160.4147.7735.71
Price / Book3.084.505.314.38
Net Income-$66.39M-$45.68M$106.18M$217.54M
7 Day Performance2.90%-1.81%-0.88%-0.14%
1 Month Performance0.61%-5.41%-3.03%-1.62%
1 Year PerformanceN/A3.38%4.22%8.90%

Lexeo Therapeutics Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRML
Tourmaline Bio
1.6044 of 5 stars		$15.92
+1.3%		$61.80
+288.2%		N/A$408.35MN/A-1.4044Short Interest ↑
News Coverage
ITOS
iTeos Therapeutics
1.6034 of 5 stars		$11.49
-2.5%		$30.33
+164.0%		+19.6%$413.30M$12.60M-3.65157News Coverage
TCRX
TScan Therapeutics
2.7362 of 5 stars		$8.65
+0.3%		$12.50
+44.5%		+59.4%$414.16M$21.05M-4.58154Upcoming Earnings
REPL
Replimune Group
4.3807 of 5 stars		$6.56
+1.2%		$37.67
+474.2%		-66.8%$402.72MN/A-2.08284Upcoming Earnings
Positive News
ADPT
Adaptive Biotechnologies
3.8414 of 5 stars		$2.93
+5.0%		$6.80
+132.1%		-50.8%$431.79M$170.28M-1.88709Earnings Report
Short Interest ↑
SLDB
Solid Biosciences
4.0415 of 5 stars		$10.23
+7.2%		$18.25
+78.4%		+67.6%$387.31M$8.09M-2.1188
AURA
Aura Biosciences
1.4018 of 5 stars		$7.77
+1.6%		$21.00
+170.3%		-28.3%$384.85MN/A-4.0588Short Interest ↑
News Coverage
CCCC
C4 Therapeutics
0.9384 of 5 stars		$6.43
-1.7%		$10.25
+59.4%		+82.2%$442.45M$20.76M-2.41145Analyst Forecast
Short Interest ↑
Analyst Revision
News Coverage
ALVO
Alvotech
0.0199 of 5 stars		$14.51
+0.2%		$12.67
-12.7%		+38.8%$453.44M$91.43M-5.971,026Upcoming Earnings
TNYA
Tenaya Therapeutics
2.6181 of 5 stars		$4.62
-1.3%		$15.40
+233.3%		-38.2%$362.76MN/A-2.77140Upcoming Earnings
Positive News

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:LXEO) was last updated on 5/11/2024 by MarketBeat.com Staff

From Our Partners
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
Colonial Metals
The Crypto 9-5 Escape Plan
Crypto 101 Media
The 2024 Gold Rush: Unleashing Market Potential
Priority Gold
Gold Set to EXPLODE!
Gold Safe Exchange
Urgent Nvidia Warning
Altimetry
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press